Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Affect Disord ; 219: 49-57, 2017 09.
Artigo em Inglês | MEDLINE | ID: mdl-28521187

RESUMO

BACKGROUND: Depression is accompanied by activated neuro-oxidative and neuro-nitrosative pathways, while targeting these pathways has clinical efficacy in depression. This study aimed to investigate the effects of mirtazapine (MIRT) alone and combined with alpha-lipoic acid (ALA) against corticosterone (CORT) induced behavioral and oxidative alterations. METHODS: Male mice received vehicle or CORT 20mg/kg during 14 days. From the 15th to 21st days they were divided in groups administered: vehicle, MIRT 3mg/kg or the combinations MIRT+ALA100 or MIRT+ALA200. On the 21st day of treatment, the animals were subjected to behavioral tests. Twenty-four hours after the last drug administration hippocampus (HC) and striatum (ST) were dissected for the determination reduced glutathione (GSH), lipid peroxidation (LP) and nitrite levels. RESULTS: CORT induced anxiety- and depressive-like behaviors as observed by increased immobility time in the tail suspension test and decreased sucrose consumption. MIRT or MIRT+ALA are effective in reversing anxiety- and depressive-like behaviors induced by CORT. CORT and MIRT alone prolonged sleeping time and this effect was reversed by MIRT+ALA. CORT significantly increased LP, which was reversed by MIRT or MIRT+ALA. Nitrite levels were increased in CORT-treated animals and reversed by MIRT+ALA200 (HC), MIRT or MIRT+ALA (ST). LIMITATION: A relative small sample size and lack of a washout period between drug administration and behavioral testing. CONCLUSIONS: MIRT or MIRT+ALA reverse CORT-induced anxiety- and depressive-like behaviors probably via their central antioxidant effects. Augmentation of MIRT with ALA may reverse sedation, an important side effect of MIRT. Randomized controlled studies are needed to examine the clinical efficacy of this combination in human depression.


Assuntos
Antidepressivos Tricíclicos/uso terapêutico , Antioxidantes/uso terapêutico , Encéfalo/efeitos dos fármacos , Transtorno Depressivo/tratamento farmacológico , Modelos Animais de Doenças , Mianserina/análogos & derivados , Ácido Tióctico/uso terapêutico , Animais , Encéfalo/metabolismo , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Corticosterona/toxicidade , Transtorno Depressivo/induzido quimicamente , Combinação de Medicamentos , Glutationa/metabolismo , Hipocampo/metabolismo , Peroxidação de Lipídeos , Masculino , Mianserina/uso terapêutico , Camundongos , Mirtazapina , Nitritos/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA